City of Hope Medical Center: Lymphoma, T-Cell trials

The registry lists 12 Lymphoma, T-Cell studies with City of Hope Medical Center as lead sponsor. 4 are open to participants now and 4 have results posted.

Phase 1 8Phase 2 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell LymphomaNot yet recruitingNCT07691450Phase 1
• Duvelisib Maintenance for the Treatment of Peripheral T-Cell LymphomasRecruitingNCT07293403Phase 2
• Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell LymphomasRecruitingNCT07278856Phase 1
• Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell LymphomaRecruitingNCT03011814Phase 1/2
• Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell LymphomasActive, not recruitingNCT03598998Phase 1/2Results posted
• Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell LymphomaCompletedNCT03534180Phase 2Results posted
• Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell LymphomaActive, not recruitingNCT03113500Phase 2Results posted
• Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron OverloadTerminatedNCT01159067Phase 2Results posted
• Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell LymphomasWithdrawnNCT03373305Phase 1
• Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin LymphomaCompletedNCT02342782Phase 1
• Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT01588015Phase 1
• Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin LymphomaTerminatedNCT01116154Phase 1